Skip to main content
Equibles

IPHA · Innate Pharma SA · Metrics

Track IPHA — free

Use IPHA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IPHA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.87 -0.01 (-0.53%) At close · Sep 11
Rebalance outlook locked
Market Cap
$208.88M
Shares
111.70M

IPHA metrics

44 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.87
Market cap
$208.88M

Price action

20 metrics
Price change (1W)
-10.1%
Price change (30D)
-14.2%
Price change (3M)
+6.3%
Price change (6M)
+24.7%
Price change (YTD)
+6.9%
Price change (1Y)
-8.3%
Trailing year
Price change (5Y)
-68.9%
52-week high
$2.54
52-week low
$1.17
Change from 52-week high
-26.2%
Change from 52-week low
+59.8%
Annualized volatility
99.0%
Annualized volatility (3M)
84.6%
Beta
1.6
RSI (14D)
40.3
Price vs SMA 50
-4.7%
Price vs SMA 200
+6.9%
Avg volume (3M)
149,149
Relative volume
0.1
Average dollar volume
$326,858

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
111.70M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-14

Profitability

9 metrics
Gross margin
—
Operating margin
-599.8%
Trailing 12 months
Net margin
-546.1%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.23

Growth

11 metrics
Revenue growth YoY
-55.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.8%
Year over year · more shares
Revenue CAGR (3Y)
-46.2%
Revenue CAGR (5Y)
-33.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-78.4%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$32.97M
Total assets
$73.61M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
10
13F filer change QoQ
+1
Institutional ownership
0.2%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.8 days to cover
Days to cover
1.8d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1598599 CUSIP 45781K204 13F (30d) 4 filings 4 filers Visit website Investor relations